Thyroid Eye Disease (Graves Orbitopathy): Pathogenesis, Clinical Features, and Management

Thyroid eye disease (TED), or Graves orbitopathy, is an autoimmune orbital disorder strongly associated with Graves hyperthyroidism. It affects 25–50% of Graves patients, with 3–5% developing moderate-severe disease. Understanding its pathophysiology guides staged, sight-saving management.

Pathogenesis

• Autoimmunity: TSH receptor (TSHR) expressed on orbital fibroblasts and adipocytes. Autoantibodies (TSI — thyroid-stimulating immunoglobulins) activate TSHR → signaling cascades (PI3K/Akt, MAPK).
• Orbital fibroblast activation: Proliferation, differentiation to adipocytes, hyaluronan (GAG) production → osmotic edema, expansion of extraocular muscles (EOMs) and orbital fat.
• Inflammation: Orbital infiltration by T cells, B cells, macrophages; cytokine release (IL-1, IL-6, TNF-α, IFN-γ).
• IGF-1R/TSHR crosstalk: IGF-1 receptor forms complex with TSHR; teprotumumab targets IGF-1R.

Clinical Course: Rundle's Curve

Active inflammatory phase (6–18 months) → plateau → inactive/fibrotic phase. Early intervention during active phase alters trajectory.

Clinical Features

• Soft tissue: Eyelid edema, chemosis, conjunctival injection, caruncle swelling.
• Eyelid retraction: Upper > lower (Dalrymple sign); lagophthalmos → exposure keratopathy.
• Proptosis: Axial displacement ≥21 mm (Hertel) or asymmetry ≥2 mm. Cosmetic concern, optic neuropathy risk.
• Restrictive strabismus: Inferior rectus > medial > superior > lateral fibrosis → limitation of elevation, abduction → diplopia.
• Dysthyroid optic neuropathy (DON): Compressive optic neuropathy at orbital apex — vision loss, color desaturation, RAPD, visual field defect. Emergency.

Assessment Tools

• CAS (Clinical Activity Score): 7-item scale (spontaneous pain, gaze-evoked pain, eyelid edema, conjunctival injection, chemosis, caruncle swelling, inflammation). ≥4/7 = active.
• VISA Classification: Vision, Inflammation, Strabismus, Appearance — guides treatment priority.
• Imaging: CT/MRI orbits — muscle enlargement (spared tendons), fat expansion, apical crowding.

Management by Disease Phase

Active Phase (Inflammatory)

• Mild (CAS <4, no DON): Lubrication, selenium (100 mcg BID ×6 mo — reduces progression), smoking cessation (critical), head elevation, botulinum for lid retraction.
• Moderate-Severe (CAS ≥4):
  • IV Methylprednisolone (IVMP): 500 mg weekly ×6, then 250 mg ×6 (cumulative 4.5g) — gold standard. Monitor LFTs, glucose, BP. Better efficacy/safety than oral.
  • Teprotumumab (Tepezza): IGF-1R inhibitor; FDA-approved 2020. 8 infusions q3wk. Dramatic proptosis/diplopia reduction. Monitor hearing, glucose, IBD flare.
  • Rituximab: Anti-CD20; emerging evidence for refractory cases.
  • Orbital radiotherapy: 20 Gy in 10 fractions; adjunct to steroids, especially for compressive optic neuropathy or motility restriction.
• DON: IVMP + urgent orbital decompression (if no improvement in 1–2 weeks).

Inactive/Fibrotic Phase (Rehabilitative)

• Orbital decompression: Medial + lateral wall ± floor; for proptosis, DON, cosmesis. May induce/new strabismus.
• Strabismus surgery: Recession of restricted muscles; after stable measurements ×6 months.
• Eyelid surgery: Retraction repair (levator recession, spacer grafts); after decompression/strabismus.

Multidisciplinary Care

Endocrinologist (thyroid control), ophthalmologist (ocular surface, motility), orbital surgeon, radiation oncologist, mental health support. Smoking cessation is the single most impactful modifiable factor.